vida: extract claims from 2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort

- Source: inbox/queue/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
 scope: correlational
 sourcer: Truveta Research
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-risk-doubles-with-prior-mental-health-history"]
 ---
 
 # GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence
@@ -31,3 +31,10 @@ Concurrent prescribing analysis shows OR 4.45 for suicidal ideation reports with
 **Source:** MDPI Nutrients PMC12694361
 
 Review identifies eating disorder history, perfectionism, OCD traits, and emotion regulation deficits as primary risk factors for GLP-1 adverse psychiatric outcomes. This extends the psychiatric comorbidity discontinuation pattern by specifying which psychiatric phenotypes create highest risk: restrictive eating disorders and obsessive-compulsive spectrum conditions rather than psychiatric comorbidity in general.
+
+
+## Extending Evidence
+
+**Source:** Lancet Psychiatry 2026, Karolinska Institutet
+
+Swedish study population (95,490 people with pre-existing depression/anxiety) demonstrates that psychiatric comorbidity is both a predictor of GLP-1 prescribing AND a population where the drug shows large protective effects (42% reduction in worsening). This creates a paradox: the population most likely to benefit faces highest discontinuation risk.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -116,3 +116,10 @@ Review confirms that GLP-1 RAs reduce binge eating disorder episodes through mes
 **Source:** Multiple clinicians (Washington Post, KTLA, Washington Times, April 2026)
 
 The same VTA dopamine circuit suppression that makes GLP-1 effective for addiction also produces broader anhedonia affecting social activities, sex, music, and pleasure generally — clinicians report patients experiencing 'emotional flattening' where they recognize positive moments but feel less excitement or connection. This suggests the mesolimbic dopamine modulation is not addiction-specific but affects general reward sensitivity.
+
+
+## Supporting Evidence
+
+**Source:** Lancet Psychiatry 2026, Karolinska Institutet
+
+Swedish national cohort (n=95,490) shows 47% reduction in substance use disorder worsening during semaglutide use periods using within-individual design that eliminates confounding. Effect size is consistent with mesolimbic dopamine mechanism and extends beyond alcohol to broader SUD category.

domains/health/semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism.md

@@ -31,3 +31,10 @@ VigiBase disproportionality analysis shows semaglutide-specific signals for depr
 **Source:** VigiBase semaglutide-specific analysis
 
 VigiBase data shows semaglutide additional psychiatric signals beyond eating disorders: depressed mood disorders (aROR 1.70), suicidality (aROR 1.45), anxiety (aROR 1.26). These signals are weaker than eating disorder signal (aROR 6.80) but suggest psychiatric effects are multi-dimensional, not uniformly protective.
+
+
+## Supporting Evidence
+
+**Source:** Lancet Psychiatry 2026, Karolinska Institutet
+
+Within-individual design in Swedish cohort (n=95,490) confirms 44% reduction in depression worsening (HR 0.56, 95% CI 0.44-0.71) during semaglutide use periods. Design eliminates time-invariant confounding that matched cohort studies cannot address.

domains/health/semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: Swedish national cohort study using within-individual design eliminates time-invariant confounding and shows large protective psychiatric effects during semaglutide use periods
+confidence: likely
+source: Lancet Psychiatry 2026, Karolinska Institutet, n=95,490
+created: 2026-05-06
+title: "Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison"
+agent: vida
+sourced_from: health/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md
+scope: causal
+sourcer: Lancet Psychiatry / Karolinska Institutet
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+challenges: ["medical-care-explains-only-10-20-percent-of-health-outcomes"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison
+
+A Swedish national registry study published in Lancet Psychiatry (March 2026) used within-individual stratified Cox models to compare psychiatric outcomes during periods when the same person was ON versus OFF semaglutide. This design eliminates all time-invariant confounding including baseline psychiatric severity, comorbidities, and social circumstances. Among 95,490 people with pre-existing depression and/or anxiety, semaglutide use was associated with 42% lower risk of composite psychiatric worsening (HR 0.58). Specific outcomes: depression worsening HR 0.56 (44% reduction), anxiety worsening HR 0.62 (38% reduction), substance use disorder worsening HR 0.53 (47% reduction), and self-harm 47% reduction. Liraglutide showed weaker effects at 18% reduction (HR 0.82). The within-individual design is the strongest quasi-experimental approach available in observational epidemiology for this question because it strips away the confounding by indication that plagues matched cohort studies. The magnitude of effect (40-50% reductions) exceeds most approved psychiatric medications for these conditions. This finding directly contradicts the 195% increased MDD risk signal from matched cohort studies by demonstrating that selection bias—people prescribed GLP-1s have more baseline psychiatric comorbidity—explains the apparent risk increase. The FDA meta-analysis of 91 RCTs (107,910 patients) showing no increased psychiatric risk converges with this Swedish finding, while the matched cohort diverges due to methodological limitations.

domains/health/within-individual-design-resolves-glp1-psychiatric-confounding-by-indication.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: "The 195% MDD risk increase in matched cohorts reflects selection bias—people prescribed GLP-1s have worse baseline mental health—while within-individual comparison shows protective effects"
+confidence: likely
+source: Lancet Psychiatry 2026 Swedish study vs Nature Scientific Reports matched cohort
+created: 2026-05-06
+title: Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies
+agent: vida
+sourced_from: health/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md
+scope: structural
+sourcer: Lancet Psychiatry / Karolinska Institutet
+related: ["glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-eating-disorder-risk-doubles-with-prior-mental-health-history", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific"]
+---
+
+# Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies
+
+The apparent divergence in GLP-1 psychiatric safety evidence—matched cohort studies showing 195% increased MDD risk versus RCTs and within-individual studies showing protective or neutral effects—is resolved by understanding confounding by indication. The Swedish Lancet Psychiatry study (March 2026) used within-individual stratified Cox models comparing the same person's psychiatric outcomes during periods ON versus OFF semaglutide. This design eliminates all time-invariant confounding including baseline psychiatric severity, unmeasured comorbidities, and social circumstances that propensity score matching cannot fully capture. The finding of 42% reduced psychiatric worsening during semaglutide use periods directly contradicts the matched cohort signal and demonstrates that the 195% MDD risk increase reflects selection bias: people prescribed GLP-1s for obesity have systematically worse baseline mental health than matched controls, even after propensity score adjustment. The FDA meta-analysis of 91 placebo-controlled RCTs (107,910 patients) showing no increased psychiatric risk converges with the within-individual finding, while matched cohort studies diverge due to residual confounding. This establishes a methodological hierarchy: within-individual designs and RCTs should dominate inference over matched cohort studies when confounding by indication is structurally present. The resolution has major implications for GLP-1 prescribing guidelines and psychiatric screening protocols.

inbox/archive/health/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md

@@ -7,10 +7,13 @@ date: 2026-03-22
 domain: health
 secondary_domains: []
 format: research-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-06
 priority: high
 tags: [GLP-1, semaglutide, mental-health, depression, anxiety, substance-use-disorder, within-individual-design, Swedish-cohort, psychiatric-safety, divergence]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content